Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody.

SM5-1 is a mouse monoclonal antibody which has a high specificity for melanoma, hepatocellular carcinoma, and breast cancer, making it a promising candidate for cancer targeting therapy. We have therefore attempted to construct a humanized antibody of SM5-1 to minimize its immunogenicity for potential clinical use. Using a molecular model of SM5-1 built by computer-assisted homology modeling, framework region (FR) residues of potential importance to the antigen binding were identified. Then, a humanized version of SM5-1 was generated by transferring these mouse key FR residues onto a human framework that was selected based on homology to the mouse framework, together with the mouse complementarity-determining region (CDR) residues. This humanized antibody retained only six murine residues outside of the CDRs but was shown to possess affinity and specificity comparable to that of the parental antibody, suggesting that it might have the potential to be developed for future clinical use.

[1]  W. Huse,et al.  Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. , 1999, Journal of molecular biology.

[2]  K. Foon,et al.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. , 1985, Cancer research.

[3]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[4]  M. Tsuchiya,et al.  Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. , 1995, Molecular immunology.

[5]  N. Tsurushita,et al.  Design of humanized antibodies: from anti-Tac to Zenapax. , 2005, Methods.

[6]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J Saldanha,et al.  Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. , 1991, Protein engineering.

[8]  S L Morrison,et al.  Genetically engineered antibodies: progress and prospects. , 1992, Critical reviews in immunology.

[9]  Yanjun Liu,et al.  SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions , 2000, Archives of Dermatological Research.

[10]  Lutz Riechmann,et al.  Reshaping human antibodies for therapy , 1988, Nature.

[11]  W. Weimar,et al.  The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients. , 1990, Transplantation proceedings.

[12]  J. Sandhu.  Protein engineering of antibodies. , 1992, Critical reviews in biotechnology.

[13]  Ya-jun Guo,et al.  Construction and characterization of a humanized anti‐human CD3 monoclonal antibody 12F6 with effective immunoregulation functions , 2005, Immunology.

[14]  K. Shitara,et al.  Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions , 2001, Cancer Immunology, Immunotherapy.

[15]  R. Colvin,et al.  Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. , 1986, Transplantation.

[16]  Ya-jun Guo,et al.  Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy , 2006, Melanoma research.

[17]  S. Kipriyanov,et al.  Generation and production of engineered antibodies , 2004, Molecular biotechnology.

[18]  J. Tso,et al.  Humanization and characterization of the anti‐HLA‐DR antibody 1D10 , 2001, International journal of cancer.

[19]  D. Norman.  Mechanisms of Action and Overview of OKT3 , 1995, Therapeutic drug monitoring.

[20]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Boulianne,et al.  Production of functional chimaeric mouse/human antibody , 1984, Nature.

[22]  Hao Wang,et al.  Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome , 2007, Cancer Immunology, Immunotherapy.

[23]  V. Roberts,et al.  Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. , 1996, Journal of immunology.

[24]  R. Owens,et al.  The genetic engineering of monoclonal antibodies. , 1994, Journal of immunological methods.

[25]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[26]  Hao Wang,et al.  Differential Expression of MART-1, Tyrosinase, and SM5-1 in Primary and Metastatic Melanoma , 2005, The American Journal of dermatopathology.

[27]  L. Presta,et al.  Humanization of an antibody directed against IgE. , 1993, Journal of immunology.